Status:
COMPLETED
Reliability and Interest of Circulating Tumor DNA in Endometrial Cancers.
Lead Sponsor:
Poitiers University Hospital
Conditions:
Circulating Tumor DNA
Endometrial Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The recent histo-prognostic molecular discoveries of the TCGA (The Cancer Genome Atlas) have shed new light on the classification of endometrial carcinomas. After carrying out different types of high...
Eligibility Criteria
Inclusion
- Histologically proven endometrial adenocarcinoma type I or type II.
- With recent abdomino-pelvic imaging, less than 3 months old.
- Tumor tissue sufficiently exploitable for research (\> 20% of tumor cells)
- Informed consent signed by the patient after clear and fair information about the study.
- Free patient, without tutorship, curatorship or subordination.
- Patient benefiting from a Social Security scheme or benefiting from it through a third person.
- Patient not opposed to participating in the study.
Exclusion
- Histologies other than adenocarcinoma (sarcoma, leiomyosarcoma)
- Linguistic or mental refusal or incapacity to understand and / or sign the informed consent
- Patients benefiting from enhanced protection, namely: minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social establishment, adults under legal protection.
- Pregnant and / or lactating women
Key Trial Info
Start Date :
June 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 8 2022
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT04456972
Start Date
June 19 2020
End Date
January 8 2022
Last Update
January 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Poitiers, PRC
Poitiers, France